Cycloset
Type 2 Diabetes
Key Facts
About Veroscience
VeroScience, founded in 2003 and based in Raleigh, NC, is a private biotech leveraging circadian neuroendocrine science to develop novel therapeutics. The company's core platform, Circadian Neuroendocrine Resetting Therapy (CNRT), underpins its approved product for type 2 diabetes (Cycloset) and a pipeline exploring applications in pediatric diabetes and oncology. Operating as a small, efficient organization, VeroScience advances its programs through nationwide preclinical/clinical research and strategic academic and industry collaborations.
View full company profileAbout Veroscience
VeroScience, founded in 2003 and based in Raleigh, NC, is a private biotech leveraging circadian neuroendocrine science to develop novel therapeutics. The company's core platform, Circadian Neuroendocrine Resetting Therapy (CNRT), underpins its approved product for type 2 diabetes (Cycloset) and a pipeline exploring applications in pediatric diabetes and oncology. Operating as a small, efficient organization, VeroScience advances its programs through nationwide preclinical/clinical research and strategic academic and industry collaborations.
View full company profileTherapeutic Areas
Other Type 2 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| Diabetes Management Gel | Gelteq Limited | Formulation Development |
| Tolimidone | Biodexa Pharmaceuticals | Phase 2 |
| Generic Semaglutide Injection (Obeda) | Dr. Reddy's Laboratories | Approved |
| BioChaperone® Lispro | Adocia | Phase 3 |
| BioChaperone® Combo (Insulin Glargine / Lixisenatide) | Adocia | Phase 2 |
| Metformin API | USV Biologics Division | Commercial |
| Empagliflozin | Azico Biophore | Commercial |
| Sitagliptin Intermediate | AR Life Science | Commercial |
| AJN003 (LuCI™) | AltrixBio | Pre-clinical |
| Sitagliptin Phosphate Polymorph | Morepen Laboratories | Pre‑clinical |
| Hepatic Denervation for Type 2 Diabetes | Metavention | Feasibility |
| MVD-1 (SANA) | Eolo Pharma | Discovery |